Key Points
- CEO sale: Jonathan Jay Mazelsky sold 23,326 shares on Feb. 26 at an average of $657.55 for about $15.34M, cutting his stake by 21.81% to 83,606 shares (≈$54.98M).
- Recent results and guidance: IDEXX reported Q4 EPS of $2.92 (missed by $0.01) and revenue of $1.09B (+14.3% YoY), and set FY2026 guidance of 14.29–14.80 EPS, versus a sell-side average forecast of ~11.93 EPS for the current year.
- Market and analyst snapshot: Shares recently opened near $636.70 with a market cap of ~$50.7B and a P/E around 48.7; the stock’s 52‑week range is $356.14–$769.98 and analysts’ average target is ~$783 with a "Moderate Buy" consensus.
IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) CEO Jonathan Jay Mazelsky sold 23,326 shares of the business's stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the sale, the chief executive officer owned 83,606 shares of the company's stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
IDEXX Laboratories Trading Down 3.0%
NASDAQ IDXX opened at $636.70 on Tuesday. The firm has a market capitalization of $50.69 billion, a price-to-earnings ratio of 48.71, a PEG ratio of 3.99 and a beta of 1.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The company's 50 day moving average price is $671.64 and its 200 day moving average price is $669.00.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the company earned $2.53 EPS. IDEXX Laboratories's revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on IDXX shares. BTIG Research lowered their target price on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research note on Tuesday, February 3rd. Barclays cut their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a report on Thursday, February 5th. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. UBS Group dropped their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a report on Tuesday, February 3rd. Finally, JPMorgan Chase & Co. raised their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $783.33.
Check Out Our Latest Analysis on IDEXX Laboratories
Hedge Funds Weigh In On IDEXX Laboratories
A number of hedge funds have recently added to or reduced their stakes in IDXX. Elyxium Wealth LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $3,666,459,000. J. Stern & Co. LLP raised its holdings in IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company's stock worth $977,210,000 after purchasing an additional 1,442,174 shares in the last quarter. Bank of New York Mellon Corp raised its stake in IDEXX Laboratories by 156.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company's stock worth $778,439,000 after buying an additional 884,808 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in IDEXX Laboratories by 318.1% during the fourth quarter. Wellington Management Group LLP now owns 779,214 shares of the company's stock worth $527,162,000 after acquiring an additional 592,834 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.
About IDEXX Laboratories
(
Get Free Report)
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
